Johnson & Johnson (JNJ) on Decifer

Decifer ranks JNJ number 204 of 277 tracked names on durable business quality.

Why it ranks here

• It earns solid returns on the money it puts to work, around 14% and it turns most of its profit into real cash.
• Revenue is expected to grow about 7% a year, profits grew 89% over the past year, and growth is speeding up, not slowing down.
• It keeps a high share of every sale as profit, and that has stayed steady over the years, a sign of real pricing power.
• and has the balance sheet to fund its growth.
• It is not watering down its owners with new shares and it returns cash to shareholders.
• Profits up 89% and momentum of 13 out of 35 help, but revenue growing only about 7% a year with no worldview role makes this dependable rather than investible for growth.

The current read

The evidence on JNJ lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• Healthcare, Biotech & Devices: Johnson & Johnson sits in the large-cap pharma layer of the Healthcare, Biotech & Devices story.

Read the full JNJ research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.